ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Black Women More Likely To Delay Diagnosis, Treatment

July 29, 2005

In Brief: Daniel Ihde Named NCI Deputy Director; Roper Is Carter consultant; Another Honor For Forei

February 8, 1991

NCI to release RFP for Cancer Information Service recompetition.

November 28, 2003

Heavy Smokers And Drinkers Have Different Brain Chemistry

May 30, 2003

In Brief: NCI Ponders How Extra $40 Million Will Be Spent, Will Submit Plans to NCAB At Upcoming Meeting

January 14, 1983

OSI “Front Line Office” In Probes Of Scientific Misconduct, Kimes Tells NCAB

October 13, 1989